

## Literaturverzeichnis zum Beitrag „Seltene Epilepsien – Seltene Erkrankungen bei Kindern und Jugendlichen“

von Professorin Dr. Regina Trollmann und Professor Dr. Hajo Hamer  
Bayerisches Ärzteblatt 7-8/2020, Seite 348 ff.

1. Auvin S, French J, Dlugos D, Knupp KG, Perucca E, Arzimanoglou A, Whalen E, Shellhaas RA. Novel study design to assess the efficacy and tolerability of antiseizure medications for focal-onset seizures in infants and young children: A consensus document from the regulatory task force and the pediatric commission of the International League against Epilepsy (ILAE), in collaboration with the Pediatric Epilepsy Research Consortium (PERC). *Epilepsia Open*. 2019;4:537–543
2. De Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, et al.; TOSCA Consortium and TOSCA Investigators. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. *Orphanet J Rare Dis*. 2018;13:157.
3. French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. *Lancet*. 2016; 388:2153-2163
4. Hamer HM, Pfäfflin M, Baier H, Bösebeck F, Franz M, Holtkamp M, Kurlemann G, May TW, Mayer T, Metzner M, Steinhoff BJ, Stodieck S, Straub HB, Weber YG, Brandt C. Characteristics and healthcare situation of adult patients with tuberous sclerosis complex in German epilepsy centers. *Epilepsy Behav*. 2018;82:64-67
5. Ho NT, Kroner B, Grinspan Z, Fureman B, Farrell K, Zhang J, Buelow J, Hesdorffer DC; Rare Epilepsy Network Steering Committee. Comorbidities of Rare Epilepsies: Results from the Rare Epilepsy Network. *J Pediatr*. 2018;203:249–258.e5
6. Jozwiak S, Kotulska K, Wong M, Bebin M. Modifying genetic epilepsies - Results from studies on tuberous sclerosis complex. *Neuropharmacology*. 2020;166:107908
7. Kölble K, Cross JH, Becker A, Blümcke I. A web-based diagnostic reference centre for the European Reference Network "EpiCare": recommendations of the eNeuropathology working group. *Epileptic Disord*. 2018;20:339–345
8. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshé SL, Peltola J, Roulet Perez E, Scheffer IE, Zuberi SM. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017; 58:522–530 (deutsche Übersetzung: *Zeitschrift für Epileptologie*; 31:272–281)
9. Marsan E, Baulac S. Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy. *Neuropathol Appl Neurobiol*. 2018;44:6–17
10. Mouthaan BE, Rados M, Barsi P, Boon P, Carmichael DW, Carrette E, Craiu D, Cross JH, et al., E-PILEPSY consortium. Current use of imaging and electromagnetic source localization procedures in epilepsy surgery centers across Europe. *Epilepsia*. 2016;57:770-776.
11. Mullier B, Wolff C, Sands ZA, Ghisdal P, Muglia P, Kaminski RM, André VM. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors. *Neuropharmacology*. 2017;123:322–331.

12. Murray S, Labbé S, Kothare S, Málaga I, Kluger G, Ogden P, Lazure P, Arzimanoglou A. Identifying the educational needs of physicians in pediatric epilepsy in order to improve care: results from a needs assessment in Germany, Spain, and the United States. *Epileptic Disord.* 2018;20:239-256
13. Nabbout R, Arzimanoglou A, Chin RFM, Grinspan Z, Speechley K, Camfield P. The evaluation and costs of transition programs for youth with epilepsy. *Epilepsy Behav.* 2019;93:133-137
14. Orsini A, Zara F, Striano P. Recent advances in epilepsy genetics. *Neurosci Lett.* 2018; 667:4-9
15. Pressler RM, Lagae L. Why we urgently need improved seizure and epilepsy therapies for children and neonates. *Neuropharmacology.* 2019 Nov 18:107854
16. Steriade C, French J, Devinsky O. Epilepsy: key experimental therapeutics in early clinical development. *Expert Opin Investig Drugs.* 2020;1–11
17. Symonds JD, McTague A. Epilepsy and developmental disorders: Next generation sequencing in the clinic. *Eur J Paediatr Neurol.* 2020;24:15–23
18. Stevelink R, Sanders MW, Tuinman MP, Brilstra EH, Koeleman BP, Jansen FE, Braun KP. Epilepsy surgery for patients with genetic refractory epilepsy: a systematic review. *Epileptic Disord.* 2018; 20:99-115
19. Tran CH, Vaiana M, Nakuci J, Somarowthu A, Goff KM, Goldstein N, Murthy P, Muldoon SF, Goldberg EM. Interneuron desynchronization precedes seizures in a mouse model of Dravet syndrome. *J Neurosci.* 2020;40:2764-2775.
20. van der Poest Clement E, Jansen FE, Braun KPJ, Peters JM. Update on drug management of refractory epilepsy in tuberous sclerosis complex. *Paediatr Drugs.* 2020;22:73-84.
21. van Karnebeek CDM, Sayson B, Lee JJY, Tseng LA, Blau N, Horvath GA, Ferreira CR. Metabolic evaluation of epilepsy: A diagnostic algorithm with focus on treatable conditions. *Front Neurol.* 2018; 9:1016
22. Wirrell EC, Nabbout R. Recent Advances in the Drug Treatment of Dravet Syndrome. *CNS Drugs.* 2019;33:867-881
23. Wolff M, Brunklaus A, Zuberi SM. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond. *Epilepsia.* 2019;60 Suppl 3:S59-S67
24. European Union - Drug development.  
[https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir\\_2001\\_83\\_consol\\_2012/dir\\_2001\\_83\\_cons\\_2012\\_en.pdf](https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf)
25. European Medicine Agency - Epileptic Disorders. Treatment guideline.  
[https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-3\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-3_en.pdf)